O
Oliver A. Cornely
Researcher at University of Cologne
Publications - 638
Citations - 35879
Oliver A. Cornely is an academic researcher from University of Cologne. The author has contributed to research in topics: Medicine & Voriconazole. The author has an hindex of 81, co-authored 541 publications receiving 27426 citations. Previous affiliations of Oliver A. Cornely include Sheba Medical Center & University of Bonn.
Papers
More filters
Journal ArticleDOI
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Oliver A. Cornely,Johan Maertens,Drew J. Winston,John R. Perfect,Andrew J. Ullmann,Thomas J. Walsh,David Helfgott,Jerzy Holowiecki,Dick Stockelberg,Yeow Tee Goh,Mario Petrini,Cathy Hardalo,Ramachandran Suresh,David Angulo-Gonzalez +13 more
TL;DR: In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazoles prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival.
Journal ArticleDOI
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
Oliver A. Cornely,Matteo Bassetti,Thierry Calandra,Jorge Garbino,Bart Jan Kullberg,O. Lortholary,O. Lortholary,Wouter Meersseman,Murat Akova,Maiken Cavling Arendrup,S. Arikan-Akdagli,Jacques Bille,Elio Castagnola,Manuel Cuenca-Estrella,J.P. Donnelly,Andreas H. Groll,Raoul Herbrecht,William W. Hope,Henrik Jeldtoft Jensen,Cornelia Lass-Flörl,George Petrikkos,Malcolm Richardson,Emmanuel Roilides,Paul E. Verweij,Claudio Viscoli,Andrew J. Ullmann +25 more
TL;DR: This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia.
Journal ArticleDOI
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Thomas J. Walsh,Hedy Teppler,Gerald R. Donowitz,Johan Maertens,Lindsey R. Baden,Anna Dmoszynska,Oliver A. Cornely,Michael R. Bourque,Robert J. Lupinacci,Carole A. Sable,Ben E. dePauw +10 more
TL;DR: Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.
Journal ArticleDOI
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Andrew J. Ullmann,José María Aguado,S. Arikan-Akdagli,David W. Denning,Andreas H. Groll,Katrien Lagrou,Cornelia Lass-Flörl,Russell E. Lewis,Patricia Muñoz,Paul E. Verweij,Adilia Warris,Florence Ader,Florence Ader,Murat Akova,Maiken Cavling Arendrup,Rosemary Ann Barnes,Catherine Beigelman-Aubry,Catherine Beigelman-Aubry,Stijn Blot,Stijn Blot,Stijn Blot,Emilio Bouza,Roger J. M. Brüggemann,Dieter Buchheidt,Jacques Cadranel,Jacques Cadranel,Elio Castagnola,Arunaloke Chakrabarti,Manuel Cuenca-Estrella,George Dimopoulos,George Dimopoulos,Jesús Fortún,Jean-Pierre Gangneux,Jorge Garbino,Werner J. Heinz,Raoul Herbrecht,Claus Peter Heussel,Christopher C. Kibbler,Nikolay Klimko,Bart Jan Kullberg,Christoph Lange,Thomas Lehrnbecher,Jürgen Löffler,Olivier Lortholary,J Maertens,O. Marchetti,Jacques F. Meis,Livio Pagano,Patricia Ribaud,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Maurizio Sanguinetti,Donald C. Sheppard,János Sinkó,Anna Skiada,Maria J G T Vehreschild,Claudio Viscoli,Oliver A. Cornely +58 more
TL;DR: Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.
Journal ArticleDOI
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
Oliver A. Cornely,Ana Alastruey-Izquierdo,Dorothee Arenz,Sharon C.-A. Chen,Eric Dannaoui,Bruno Hochhegger,Bruno Hochhegger,Martin Hoenigl,Martin Hoenigl,Henrik Jeldtoft Jensen,Katrien Lagrou,Russell E. Lewis,Sibylle C. Mellinghoff,Mervyn Mer,Zoi D. Pana,Danila Seidel,Donald C. Sheppard,Roger Wahba,Murat Akova,Alexandre Alanio,Abdullah M. S. Al-Hatmi,Sevtap Arikan-Akdagli,Hamid Badali,Ronen Ben-Ami,Alexandro Bonifaz,Stéphane Bretagne,Elio Castagnola,Methee Chayakulkeeree,Arnaldo Lopes Colombo,Dora E. Corzo-Leon,Lubos Drgona,Andreas H. Groll,Jesús Guinea,Jesús Guinea,Claus Peter Heussel,Ashraf S. Ibrahim,Souha S. Kanj,Nikolay Klimko,Michaela Lackner,Frédéric Lamoth,Fanny Lanternier,Cornelia Lass-Floerl,Dong-Gun Lee,Thomas Lehrnbecher,Badre E. Lmimouni,Mihai Mares,Georg Maschmeyer,Jacques F. Meis,Joseph Meletiadis,Joseph Meletiadis,C. Orla Morrissey,Marcio Nucci,Rita O. Oladele,Livio Pagano,Alessandro C. Pasqualotto,Atul Patel,Zdenek Racil,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Seyedmojtaba Seyedmousavi,Seyedmojtaba Seyedmousavi,Neeraj Sidharthan,Nina Singh,Janos Sinko,Anna Skiada,Monica A. Slavin,Monica A. Slavin,Rajeev Soman,Brad Spellberg,William J. Steinbach,Ban Hock Tan,Andrew J. Ullmann,Joerg J. Vehreschild,Maria J G T Vehreschild,Thomas J. Walsh,P. Lewis White,Nathan P. Wiederhold,Theoklis E. Zaoutis,Arunaloke Chakrabarti +79 more
TL;DR: Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.